Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

In prurigo nodularis, ruxolitinib cream significantly improves itch and treatment success, indicating its potential as a novel therapy. Two posters presented at the 2025 American Academy of ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN ... After 12 weeks of treatment, 44.6% of ...

The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN ... a novel approach for the treatment of PN,” Kwatra ...

Given the late-breaking data on topical ruxolitinib's effectiveness in prurigo nodularis and its rapid itch relief, how do you foresee this impacting treatment paradigms for chronic pruritic ...

The first one being that it was able to report positive data from one of its two phase 3 studies using OPZELURA [Ruxolitinib Cream 1.5%] for the treatment of patients with Prurigo Nodularis [PN].

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Treatment-emergent adverse events (TEAEs ... et al "Efficacy and safety of ruxolitinib cream in patients with prurigo nodularis: Results from a phase III, randomized, vehicle-controlled study ...

chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries ...